EPHA3 Could Be a Novel Prognosis Biomarker and Correlates with Immune Infiltrates in Bladder Cancer.

ABSTRACT:

Purpose

To assess the mechanism of EPH receptor A3 (EPHA3) and its potential value for immunotherapy in BLCA.

Materials and methods

The Cancer Genome Atlas (TCGA) bladder cancer (BLCA) database and the Gene Expression Omnibus (GEO) database were used for assessing whether EHPA3 could be used to predict BLCA prognosis. This work carried out in vitro and in vivo assays for exploring how EPHA3 affected the biological behaviors. The downstream pathway was explored using a Western blotting technique. The CIBERSORT, ESTIMATE, TIMER, and TIDE tools were used to predict the immunotherapy value of EPHA3 in BLCA.

Results

EPHA3 was poorly expressed in BLCA (p < 0.05), its high expression is related to a good survival prognosis (p = 0.027 and p = 0.0275), and

SUBMITTER: Liu J 

PROVIDER: S-EPMC9913674 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature